

F. No. 12-01/18-DC (Pt-337)
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(New Drugs Division)

FDA Bhawan, Kotla Road,
New Delhi-110002.

Dated: **19 JUN 2019**

To,

All State/UT Drugs Controllers,

**Sub: Carbamazepine – Drug Rash with Eosinophilia and Systemic
Symptoms (DRESS) - Reg.**

Sir,

Carbamazepine is approved by CDSCO and marketed in the country.

The National Co-ordination Centre for Pharmacovigilance Programme of India (NCC-PvPI), functioning at IPC Ghaziabad has forwarded their recommendation based on ADR reports on certain medicinal products including Carbamazepine which were discussed by them in the 12th Signal Review Panel (SRP) under the programme meeting held on 27.03.2018 with an objective to detect Signal/Prescribing Information Leaflet change from Indian database and promote patient safety.

In the meeting, the PvPI has evaluated the drug Carbamazepine -ADR on the basis of Individual Case Study Reports (ICSR) and recommended CDSCO to take necessary steps to incorporate Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) in to the prescribing information leaflet (PIL) of the drug Carbamazepine marketed in the country.

Subsequently, the PvPI recommendations was deliberated in the Subject Expert Committee (SEC-Neurology & Psychiatry) meeting held on 12.06.2019 at CDSCO HQ, New Delhi. After detailed deliberation the Committee has recommended that Drug Rash with Eosinophilia and Systemic Symptoms

(DRESS) should be incorporated as an adverse drug reaction in the package insert of the drug Carbamazepine as suggested by PvPI.

The recommendation of the SEC has been considered by this office. Accordingly, you are requested to direct the manufacturers of Carbamazepine formulations under your jurisdiction to mention Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) as an adverse drug reaction in the Package Insert/Promotional Literature of the drug.

Action taken in this regard may be intimated to this office.

Yours faithfully,



Dr. S. Eswara Reddy
Drugs Controller General (India)

1. Copy for information & follow-up: -
All Zonal / Sub Zonal Offices of CDSCO.
2. Copy for information to: -
JS(R), Nirman Bhawan, MoHFW, New Delhi-110002.